Prestige Consumer Healthcare (PBH) investor relations material

Strategic overview and brand portfolio

• Three-pillar strategy: invest in brands, maintain strong financials, and deploy capital effectively remains unchanged despite macro volatility.

• Growth driven by leading brands in niche, need-state categories with strong margins and low promotional activity.

• Recent acquisitions (Breathe Right and LaCorium Health) align with the strategy, expanding presence in respiratory and therapeutic skincare.

• International segment targeted for 5%+ top-line growth, aiming to increase from 15% to 20% of total sales.

• Brand-building playbook leverages consumer insights to drive innovation and category leadership.

Recent acquisitions and integration

• Breathe Right acquisition closed in June, with strong brand awareness but low household penetration, offering significant growth runway in North America and internationally.

• LaCorium Health, anchored by Dermal Therapy, has shown double-digit growth, with 75% of sales in Australia and plans for international expansion.

• Integration of Breathe Right largely complete; LaCorium integration ongoing with support from former staff and seller.

• Both acquisitions expected to accelerate international growth and diversify the portfolio.

Eye care business update

• Clear Eyes now represents about 3% of sales, with recent investments in infrastructure, equipment, and leadership at the Canadian facility.

• Near-term supply variability expected, with sequential improvement anticipated each quarter and more consistent supply by fiscal 2027.

• Focus remains on quality and rebuilding retailer trust after industry recalls.

• Long-term plan includes restoring inventory, reintroducing SKUs, and resuming marketing.